Skip to Content
Enter
Skip to Menu
Enter
Skip to Footer
Enter
X

Request a demo

Please kindly fill out the form below and a member of our team will be touching base with you shortly.

By submitting this form, you submit your information to Biorelate, who may use it to communicate with you regarding your request via the form and their other services. You may unsubscribe from these communications at any time by clicking the Unsubscribe button at the bottom of our marketing emails or contacting us at info@biorelate.com.

We will be in touch shortly via email.
Thanks for your request.
Oops! Something went wrong while submitting the form.

Daniel Jamieson awarded The Princess Royal Silver Medal

July 9, 2024
•
5 min read
Basic Linkedin Icon Basic Pinterest Icon Basiic Maill iicon
Biorelate News

Latest News

Discover new insights and updates for data science in biopharma. Follow Biorelate on LinkedIn for the latest news, events and webinars updates.

July 9, 2024

Daniel Jamieson awarded The Princess Royal Silver Medal

Biorelate Founder and CEO is one of four to be presented with one of the Royal Academy of Engineering’s most prestigious individual awards

Staying AI-head of the game!

Staying AI-head of the game!

Gen AI’s real opportunity in drug development? As a smart, strategic decision aid

Gen AI’s real opportunity in drug development? As a smart, strategic decision aid (Drug Discovery Today)

GenAI’s Real Potential in Biopharma: As a Cross-Function R&D Assistant

GenAI’s Real Potential in Biopharma: As a Cross-Function R&D Assistant (BioIT World)

Siloed use of Gen AI will limit its transformation potential

Siloed use of Gen AI will limit its transformation potential

AstraZeneca's innovative graph as a service and generative AI models: is this the future of data science?

Antonio Fabregat, Knowledge Graph Lead at AstraZeneca, recently presented on the innovations to make data more accessible and insightful for internal biopharma research customers.

What does ‘speed to cycle’ mean for the pharmaceutical industry and why does it matter so much?

Pharmas already have standardised protocols to help them get to the right decision, but it takes them a long time to get there.

The limitations of named entity recognition in the era of LLMs, NLP and text mining for drug discovery: the case study of P40

Named entity recognition for genes and proteins creates challenges for drug discovery researchers which, luckily, can be overcome by NLP and LLM-curated text mining

The what, why and how of LLMs in drug discovery - what top pharma thought leaders have to say

To get beyond the universal hype and buzz around ChatGPT, Generative Artificial Intelligence (AI), and Large Language Models (LLMs), ubiquitous across all industries, we brought together biopharma thought leaders to dive into what is hallucination and what is real.

GenAI and LLMs to potentially 'revolutionise' drug discovery - what top pharma thought leaders have to say

GenAI and LLMs to potentially 'revolutionise' drug discovery - what top pharma thought leaders have to say

Generative AI for Drug Discovery in the era of ChatGPT: The Top 7 Key Considerations For Biopharma

Generative AI for Drug Discovery in the era of ChatGPT: The Top 7 Key Considerations For Biopharma

Daniel Jamieson awarded The Princess Royal Silver Medal

Biorelate Founder and CEO is one of four to be presented with one of the Royal Academy of Engineering’s most prestigious individual awards

Galactic AI™ represents a quantum leap in the field of biomedical literature search and curation

By leveraging the power of Galactic AI™, researchers can accelerate the pace of discovery and innovation in the biomedical field, leading to breakthroughs in understanding, preventing, and treating diseases.

Request demoLearn more